Autolus Therapeutics announces publication in Nature Communications
February 22, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces publication in Nature Communications
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
June 16, 2023 07:00 ET
|
Autolus Therapeutics plc
At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A)Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months...
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
December 12, 2022 10:00 ET
|
Autolus Therapeutics plc
Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia...
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
November 03, 2022 09:31 ET
|
Autolus Therapeutics plc
obe-cel: poster presentation in B-ALL and B-NHL patientsAUTO1/22: poster presentation in pediatric ALL patientsAUTO4: poster presentation in T-Cell Lymphoma patients LONDON, Nov. 03, 2022 ...
Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress
June 10, 2022 03:01 ET
|
Autolus Therapeutics plc
- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma- AUTO1/22 demonstrates encouraging and durable responses in children ineligible for...
Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress
May 12, 2022 10:51 ET
|
Autolus Therapeutics plc
- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia-...
Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor constant region beta chain 1 (TRBC1) positive T cell lymphomas
April 20, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...